The Accreditation Council for Medical Affairs (ACMA) announced today the appointment of Sotirios G. Stergiopoulos, MD, MBEE, BCMAS as new President of the ACMA Board of Governors

NEW YORK, Oct. 10, 2017 — The Accreditation Council for Medical Affairs (ACMA), a leading organization within medical affairs in the pharmaceutical industry has appointed Dr. Sotirios G. Stergiopoulos as President of the ACMA Board of Governors.

Dr. Stergiopoulos is currently the Senior Vice President & Head of Global Medical Affairs at Ipsen Bioscience.  He has extensive experience in directing medical affairs worldwide strategies and plans and a solid expertise in Oncology drug development that includes chemotherapy, immunology drugs and targeted agents across various tumor indications. His past experience includes Vice President, Head of Global Medical Affairs Oncology at Baxalta (now Shire, Cambridge, MA), Executive Medical Director Oncology US Medical Affairs at Celgene Corporation (Summit, NJ), Senior Global Brand Medical Director Oncology at Novartis Pharmaceuticals (East Hanover, NJ) and Director Medical Affairs Oncology at Bayer Healthcare (Montville, NJ).

“Sotirios brings an extensive background in medical affairs to the ACMA and is a well-respected thought leader within the pharmaceutical industry,” said Dr. William A. Soliman, Executive Chair of the ACMA.  “We are excited to have him as president of our board.”

“I am honored that the ACMA has appointed me as President of the Board of Governors. The ACMA has an important mission which will help improve the quality of pharmaceutical industry professionals worldwide and therefore improve patient care” said Dr. Stergiopoulos.

Leave a Reply